as informed in empr
Investigational Shingles Vaccine Evaluated in Patients 70 Years and Older
Investigational Shingles Vaccine Evaluated in Patients 70 Years and Older
Investigational Shingles Vaccine Evaluated in Patients 70 Years and OlderA total of 14,800 patients aged ≥70 were included in the trialGlaxoSmithKline (GSK) announced the publication of results from The Phase 3 study, ZOE-70, evaluating the investigational shingles vaccine, Shingrix, in patients aged 70 years and older.Detailed study findings were published in the New England Journal of Medicine (NEJM).ZOE-70 (ZOster Efficacy in adults aged 70 years and over) was a global, multicenter, randomized, observer-blind, placebo-controlled, Phase 3 trial evaluating the efficacy, safety and immunogenicity of Shingrix in 14,800 patients aged 70 years and older.
in the same way ontario
Ontario Making Shingles Vaccine Free for Seniors
Ontario Making Shingles Vaccine Free for Seniors
Ontario Making Shingles Vaccine Free for SeniorsFirst-in-Canada Program Will Save Seniors Money and Support Healthy AgingSeptember 15, 2016 1:00 P.M. Ministry of Health and Long-Term CareOntario is the first jurisdiction in Canada to provide the shingles vaccine free of charge, saving eligible seniors approximately $170 and helping them stay healthy.Starting today, the shingles vaccine will be available across the province for people 65 to 70 years of age.The government is investing $68 million over three years in order to publicly fund the vaccine, which will reduce the likelihood of Ontario seniors developing the painful infection, and reduce visits to emergency rooms and hospitals.
by the same token on zacks
Glaxo (GSK) Publishes Phase III Data on Shingles Vaccine
Glaxo (GSK) Publishes Phase III Data on Shingles Vaccine
Keep Me Signed In What does "Remember Me" do?You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer.ZacksTrade and Zacks.com are separate companies.
No comments:
Post a Comment